The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

It’s incredible to see these groundbreaking medications come to market for patients. Obesity is an epidemic affecting 100 million Americans. Doctors, insurers, policymakers and employers must ...

We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss.” ...

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare costs. Lifestyle changes and improved diets are critical but often ...

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) formulation of its experimental obesity drug VK2735 in adult patients with ...

Many semaglutide users deviate from recommended dose‐escalation schedules and discontinue treatment, highlighting the need for policy interventions to reduce financial barriers.